This study was designed to compare the efficacy and safety of Becotatug Vedotin (MRG003) combined with Pucotenlimab as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Aged 18 to 75 years on the day of signing the informed consent form (or the legal age of consent in the jurisdiction in which the study is taking place).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy ≥ 3 months.
Histologically or cytologically confirmed nasopharyngeal carcinoma (NPC).
Peripheral neuropathy of Grade 2 or higher.
Anticipated need for any other local or systemic anti-tumor therapy during the study period.
Diagnosed and/or treated additional malignancy within 5 years of enrollment, with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin, and/or curatively-resected in situ cervical and/or breast carcinoma.
Active central nervous system (CNS) metastases or carcinomatous meningitis.